Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
A secondary analysis of the LEADER trial to investigate the safety of liraglutide in patients with type 2 diabetes.
Read More »Liraglutide Linked to Gallbladder Complications
Phase 3 Comparison Trial: GLP-1 vs DPP-4
A recent study demonstrates the efficacy of a new, once daily oral option for patients with type 2 diabetes already on metformin.
Read More »Exenatide Reduces Risk of MACE for Type 2 Diabetes Patients
Exenatide joins trend of GLP-1 agonists showing benefit for patients with established CVD.
Read More »Liraglutide and Sitagliptin Useful for Nonalcoholic Fatty Liver Disease in T2DM
A recent study reveals Liraglutide and Sitagliptin reduce intrahepatic lipid in patients with T2DM and IHL.
Read More »CV Benefit of GLP-1 Agonists and SGLT2 Inhibitors Misleading for Black Patients? ADA
Claims of improved cardiovascular outcomes from GLP-1 agonists and SGLT2 inhibitors not proven significant for black patients.
Read More »PIONEER 5 Study Validates Oral GLP-1 Effectiveness
The PIONEER 5 study discusses the safety and efficacy of the first oral GLP-1 receptor agonist, a potential substitute to injections.
Read More »Cardiovascular Benefits of Oral GLP-1RA in High-Risk Patients with Type 2 Diabetes
Results from the recently published PIONEER trial series demonstrate the overall diabetic benefits of oral semaglutide, a novel GLP-1 receptor agonist.
Read More »Liraglutide for Youth with Type 2 Diabetes
The lack of studies for children and adolescents with type 2 diabetes has led to an absence of approval of new drugs for this patient population. This study reports findings of Liraglutide for youth.
Read More »Oral Semaglutide vs Subcutaneous GLP-1RAs — ADA 2019
New research findings on oral semaglutide vs subcutaneous liraglutide.
Read More »Liraglutide Lowers Risk of Cardiovascular Events In Type 2 Diabetes
GLP-1 treatment benefits patients on statins and with varying LDL levels.
Read More »